Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

26.76 +0.56 (+2.14%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
News headline image
Are Wall Street Analysts Bullish on Pfizer Stock?
Pfizer has underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects. 
Via Barchart.com
Topics ETFs Intellectual Property
News headline image
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal ↗
Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus. 
Via The Motley Fool
Topics Stocks
News headline image
Is Bristol Myers Squibb the Best Bargain in Big Pharma? ↗
This pharma stock is cheap for a reason. 
Via The Motley Fool
Topics Intellectual Property
News headline image
VCIT vs. IEI Comes Down to What Job Your Bond Sleeve Is Doing ↗
Explore how differences in bond type, risk, and income potential set these two popular ETFs apart for investors. 
Via The Motley Fool
Topics Bonds ETFs
News headline image
Is This Tech Giant the Next Potential Winner in the GLP-1 Weight Loss Boom? ↗
The weight loss drug market may reach almost $100 billion in a few years. 
Via The Motley Fool
News headline image
Is Pfizer's 6% Dividend Yield Safe? Here's What Investors Need to Know. ↗
Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out. 
Via The Motley Fool
Topics Earnings
These S&P500 stocks are the most active in today's session ↗
Via Chartmill
News headline image
Unusual Put Activity Is Flagging a Smart Trade Setup in This New Quantum Computing Stock
Quantum computing firm Infleqtion led Thursday with a 133.59 Vol/OI ratio. The Jan. 15/2027 $10 put made up 23% of volume, which was 2.8 times its 30-day average, making the trade sneaky smart. Here’s... 
Via Barchart.com
Topics Artificial Intelligence Initial Public Offering
News headline image
Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.
A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside. 
Via Barchart.com
News headline image
Pfizer Declares Second-Quarter 2026 Dividend
From Pfizer Inc.
Via Business Wire
News headline image
Should You Forget Pfizer and Buy This Pharma Stock Instead? ↗
Pfizer's shares have rebounded, but is AbbVie still a better buy among pharmaceutical stocks? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Why Merck (MRK) Shares Are Trading Lower Today
What Happened? Shares of global pharmaceutical company Merck (NYSE:MRK) fell 3.8% in the afternoon session after the company, along with its partner Eisai, a... 
Via StockStory
Topics Government Intellectual Property
News headline image
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
From Pfizer Inc.
Via Business Wire
News headline image
A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly ↗
There might be room for two titans in the obesity business, but a third player might have a uniquely marketable option. 
Via The Motley Fool
News headline image
This Drug Stock Has Crushed the S&P 500 Over the Last Decade ↗
Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Where Will Pfizer Stock Be in 3 Years? ↗
The healthcare giant has been investing heavily in its future growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better Long-Term Buy: Eli Lilly or Viking Therapeutics? ↗
One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
2 Value Stocks to Research Further and 1 Facing Headwinds
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
QSM Asset Management Loads Up 611,000 Mobileye Shares ↗
Mobileye develops advanced driver assistance and autonomous driving technologies for global automotive manufacturers and suppliers. 
Via The Motley Fool
Topics Economy Regulatory Compliance Supply Chain
News headline image
A Fund Just Bet $5.7 Million on Robert Half -- Is the Staffing Sector Due for a Rebound? ↗
Robert Half Inc. provides staffing and risk consulting solutions globally to employers across diverse industries. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Look for Before Buying a Pharma Stock ↗
Start with the drug pipeline when researching pharma stocks to own. 
Via The Motley Fool
Topics Intellectual Property
News headline image
QSM Asset Management Bets on Beaten-Down Manpower Group With New $5.9 Million Stake in ManpowerGroup ↗
ManpowerGroup provides staffing and HR solutions worldwide, serving clients in 75 countries. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Earnings Preview: What to Expect From Pfizer’s Report
Pfizer is set to report its first-quarter earnings next month, with analysts expecting profits to decline in the low double-digit range. 
Via Barchart.com
News headline image
Investing $8,000 In Each of These 3 Stocks in 2026 Could Generate $1,500 in Annual Dividends ↗
These stocks have been struggling in recent years, but they are safer investments than they appear to be at first glance. 
Via The Motley Fool
Topics World Trade
News headline image
The New J&J: A 2026 Deep Dive into the Global Healthcare Titan
As of April 14, 2026, Johnson & Johnson (NYSE: JNJ) stands as a radically different entity than it was only three years ago. Following the successful spin-off of its consumer health division, Kenvue,... 
Via Finterra
Topics Artificial Intelligence Death Economy
News headline image
Dividend Stock Guru Unveils High Yield Dividend Stock Research Reports
Via PRLog
News headline image
Better Buy Right Now: Johnson & Johnson Vs. Pfizer ↗
The choice is based on more than just the dividend payout. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
A Healthcare Stock With a 6%-Plus Yield: Is the Dividend Safe? ↗
The company has increased its payouts over the past five years despite significant challenges. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.